Recently, it has been reported that a moderate to high percentage of gastric cancer tumor samples have CD133 expression with moderate to strong membranous and apical expression [6], which identifying that CD133 could be acted as a potential therapeutic target for antibody–drug conjugates in gastric carcinoma, and raising the possibility of molecular targeting therapy in the most aggressive malignancy. Here, PROM1 is linked to gastric cancer.